Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Disease (AIM) Rheumatoid Arthritis
If you participate you will be asked to come in for a screening to determine eligibility for a synovial biopsy of your wrist, knee, or ankle. You will also be asked to complete health questionnaires and have your blood drawn. You may be compensated up to $305 for completion of 3 visits over a 24-week period.
MoreAdult
Subjects must be 18 years old or older Subjects must meet 2010 ACR/EULAR classification criteria or erosion consistent with RA Subjects must be less than 1 year from diagnosis of Rheumatoid Arthritis (RA) Subjects must be positive for anti-CCP or Rheumatoid Factor Subjects must have 1 or more swollen or tender joint
Subjects cannot be on prednisone of more than 10mg once a day for more than 7 days leading up to enrollment Subjects may not be taking hydroxychloroquine (Plaquenil) for more than 2 weeks prior to enrollment Subjects may not be taking Methotrexate (MTX) for more than 2 weeks prior to enrollment
Observational
Barbara Davis Center
University of Colorado Hospital
Larry Moreland, MD
Protocol Number: 23-0022
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers